ABCL logo

AbCellera Biologics Inc. (ABCL)

$11.12

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ABCL

Market cap

$3.63B

EPS

-0.48

P/E ratio

--

Price to sales

61.41

Dividend yield

--

Beta

1.596249

Price on ABCL

Previous close

$11.49

Today's open

$11.23

Day's range

$11.03 - $11.44

52 week range

$2.75 - $15.02

Profile about ABCL

CEO

Carl Hansen

Employees

562

Headquarters

Vancouver, BC

Exchange

Nasdaq Global Select

Shares outstanding

326617896

Issue type

Common Stock

ABCL industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ABCL

AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript

AbCellera Biologics Inc. (ABCL) Presents at UBS Global Biopharma Conference 2026 Transcript

news source

Seeking Alpha • 13 hours ago

news preview

AbCellera Biologics Targets 2027 Late-Stage Trial for Hot Flash Treatment

AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot flash treatment ABCL635 into late-stage studies, with a registrational trial potentially starting around the middle of 2027, Chief Executive Carl Hansen said at the Jefferies 2026 Global Healthcare Conference in London.

news source

MarketBeat • Nov 16, 2026

news preview

AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

AbCellera Biologics Inc. ( ABCL ) Stifel 2026 Healthcare Conference 2026 November 10, 2026 7:00 PM EST Company Participants Carl L. Hansen - CEO, President & Chairperson Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Stephen Willey Stifel, Nicolaus & Company, Incorporated, Research Division All right.

news source

Seeking Alpha • Nov 13, 2026

news preview

AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results

AbCellera Biologics NASDAQ: ABCL is preparing to advance its experimental hot-flash treatment ABCL635 into late-stage development next year after a midstage study produced stronger-than-expected efficacy results, CEO Carl Hansen said at a Stifel event.

news source

MarketBeat • Nov 12, 2026

news preview

Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Editas Medicine (EDIT) have performed compared to their sector so far this year.

news source

Zacks Investment Research • Nov 12, 2026

news preview

What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call

AbCellera Biologics NASDAQ: ABCL plans to advance its experimental hot flash treatment ABCL635 into late-stage development in 2027 after reporting positive mid-stage results, while shelving further development of a separate antibody candidate for now.

news source

MarketBeat • Nov 10, 2026

news preview

AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 10, 2026

news preview

AbCellera Reports Q3 2026 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2026 Business Results.

news source

Business Wire • Nov 9, 2026

news preview

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.19 per share a year ago.

news source

Zacks Investment Research • Nov 9, 2026

news preview

AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at the UBS Global Biopharma Conference on November 17, 2026.

news source

Business Wire • Nov 5, 2026

news preview

¹ Disclosures

Get started with M1

Invest in AbCellera Biologics Inc.

Open an M1 investment account to buy and sell AbCellera Biologics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ABCL on M1